Literature DB >> 32726650

Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines.

Nadia Fattahi1, Mohammad-Ali Shahbazi2, Aziz Maleki3, Mehrdad Hamidi4, Ali Ramazani5, Hélder A Santos6.   

Abstract

Many drug molecules that are currently in the market suffer from short half-life, poor absorption, low specificity, rapid degradation, and resistance development. The design and development of lipophilic prodrugs can provide numerous benefits to overcome these challenges. Fatty acids (FAs), which are lipophilic biomolecules constituted of essential components of the living cells, carry out many necessary functions required for the development of efficient prodrugs. Chemical conjugation of FAs to drug molecules may change their pharmacodynamics/pharmacokinetics in vivo and even their toxicity profile. Well-designed FA-based prodrugs can also present other benefits, such as improved oral bioavailability, promoted tumor targeting efficiency, controlled drug release, and enhanced cellular penetration, leading to improved therapeutic efficacy. In this review, we discuss diverse drug molecules conjugated to various unsaturated FAs. Furthermore, various drug-FA conjugates loaded into various nanostructure delivery systems, including liposomes, solid lipid nanoparticles, emulsions, nano-assemblies, micelles, and polymeric nanoparticles, are reviewed. The present review aims to inspire readers to explore new avenues in prodrug design based on the various FAs with or without nanostructured delivery systems.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Drug delivery; Fatty acids; Nanomedicine; Prodrugs

Mesh:

Substances:

Year:  2020        PMID: 32726650     DOI: 10.1016/j.jconrel.2020.07.012

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

Review 1.  Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles.

Authors:  Sifei Han; Lianghe Mei; Tim Quach; Chris Porter; Natalie Trevaskis
Journal:  Pharm Res       Date:  2021-08-31       Impact factor: 4.200

Review 2.  Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy.

Authors:  Wenjie Zhang; Reza Taheri-Ledari; Fatemeh Ganjali; Fereshte Hassanzadeh Afruzi; Zoleikha Hajizadeh; Mahdi Saeidirad; Fateme Sadat Qazi; Amir Kashtiaray; Samin Sadat Sehat; Michael R Hamblin; Ali Maleki
Journal:  Heliyon       Date:  2022-06-02

3.  Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor.

Authors:  Xu-Dong Wang; Wei-Jia Yu; Jia-Hui Liu; Jie Du; Kang-Nan Chen; Qin-Qin Hu; Wen-Long Sun; Guo-Qing Ying
Journal:  Front Bioeng Biotechnol       Date:  2022-05-23

Review 4.  Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy.

Authors:  Diedie Li; Chengzhi Gao; Meiyan Kuang; Minhao Xu; Ben Wang; Yi Luo; Lesheng Teng; Jing Xie
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

5.  Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.

Authors:  Rujing Chen; Shuting Ni; Wangyan Chen; Mei Liu; Jianfang Feng; Kaili Hu
Journal:  Int J Nanomedicine       Date:  2021-08-03

Review 6.  Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.

Authors:  Lingling Huang; Jianmiao Yang; Tiantian Wang; Jianqing Gao; Donghang Xu
Journal:  J Nanobiotechnology       Date:  2022-01-24       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.